Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Long-Term Investments (2021 - 2024)

Zentalis Pharmaceuticals has reported Long-Term Investments over the past 4 years, most recently at $349.9 million for Q3 2024.

  • For Q3 2024, Long-Term Investments changed N/A year-over-year to $349.9 million; the TTM value through Sep 2024 reached $349.9 million, changed N/A, while the annual FY2023 figure was $454.9 million, 2044.35% up from the prior year.
  • Long-Term Investments for Q3 2024 was $349.9 million at Zentalis Pharmaceuticals, down from $389.4 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $454.9 million in Q4 2023 and troughed at $18.9 million in Q1 2023.
  • A 4-year average of $181.7 million and a median of $36.6 million in 2021 define the central range for Long-Term Investments.
  • Biggest five-year swings in Long-Term Investments: tumbled 47.12% in 2023 and later skyrocketed 2288.19% in 2024.
  • Year by year, Long-Term Investments stood at $37.5 million in 2021, then plummeted by 43.42% to $21.2 million in 2022, then skyrocketed by 2044.35% to $454.9 million in 2023, then decreased by 23.07% to $349.9 million in 2024.
  • Business Quant data shows Long-Term Investments for ZNTL at $349.9 million in Q3 2024, $389.4 million in Q2 2024, and $451.4 million in Q1 2024.